Getinge Stock Falls as Lawsuits Mount: Getinge Sells Off Atrium’s C-Qur Hernia Mesh Line

Atrium Medical Corporation has announced that it has signed an agreement selling its entire bio-surgery business, including the C-Qur hernia mesh line to HJ Capital 1 and its subsidiary of SeCQure Surgical Corporation. The Swedish medical company Getinge previously purchased Atrium and its biosurgery business in 2011 for $680 million. However, Atrium’s biosurgery segment only had $14 million in total sales for 2017 and was subject to nearly 1,000 lawsuits regarding the C-Qur hernia mesh. It has not yet been disclosed how much Atrium’s bio-surgical department was sold for, but it was noted that HJ Capital 1 and SeCQure Surgical would not be acquiring the liability of the C-Qur lawsuits currently pending against Atrium and Getinge. It is currently unclear why any company would acquire the dangerous C-Qur hernia mesh product line. It’s hard to believe that any company could continue to sell the C-Qur hernia mesh after so many substantiated lawsuits alleging significant injuries and even death have been filed related to the C-Qur hernia mesh. Atrium has been unable to safely manufacturer the C-Qur hernia mesh for over a decade, and it’s unlikely that HJ Capital 1 or SeCQure Surgical Corporation will be able to make a safer product. We hope that the sale of Atrium’s bio-surgical department gets us one step closer to the C-Qur hernia mesh never being sold again. The FDA has failed to take effective action against the C-Qur hernia mesh; however, the economic and investigatory pressures that attorneys nationwide have been putting on Atrium and Getinge are clearly having an impact.